BOSTON– Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, announced the pricing of an underwritten registered direct offering totaling approximately $80 million in gross proceeds.
The offering includes 70,001,000 shares of common stock and pre-funded warrants to purchase an additional 10,000,000 shares. The shares are being sold at $1.00 each, while the pre-funded warrants are priced at $0.9999 per warrant, reflecting the per-share price of the common stock less the $0.0001 per share exercise price. All securities are being offered by Adicet. The transaction is expected to close on or about October 8, 2025, pending customary closing conditions.
Jefferies and Guggenheim Securities are acting as joint book-running managers for the offering, with Truist Securities also serving as a joint bookrunner. Wedbush PacGrow and H.C. Wainwright & Co. are acting as lead managers.
The securities are being offered pursuant to Adicet’s shelf registration statement on Form S-3 (File No. 333-285609), which was declared effective by the U.S. Securities and Exchange Commission (SEC) on March 14, 2025.
